Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$892.48 USD
+9.28 (1.05%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $893.96 +1.48 (0.17%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$892.48 USD
+9.28 (1.05%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $893.96 +1.48 (0.17%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth A Momentum D VGM
Zacks News
The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Ophthotech and Exelixis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Ophthotech and Exelixis
Biotech Stock Roundup: Ophthotech Slumps on Fovista Results, Achaogen Skyrockets on Data
by Arpita Dutt
Several companies presented data this week with companies like Achaogen (AKAO) soaring while others like Ophthotech plunged.
Ophthotech Hits 52-Week Low on Unfavorable Fovista Data
by Zacks Equity Research
Ophthotech's (OPHT) shares tumbled 86.4% to a 52-week low after the company reported disappointing phase III data on its eye drug, Fovista, in wet AMD patients.
3 Great Stocks to Beat the Biotech Blues
by Arpita Dutt
Are you on the lookout for some good biotech stocks this month? Here are three that warrant a look.
Should Biotech Investors Worry About Donald Trump?
by Arpita Dutt
It looks like biotech investors may have heaved a sigh of relief a bit too early when Presidential election results were announced last month.
The Zacks Analyst Blog Highlights: Booz Allen Hamilton Holding, McDonald's, Regions Financial and Regeneron Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Booz Allen Hamilton Holding, McDonald's, Regions Financial and Regeneron Pharmaceuticals
Play the Trump Factor with these 4 Large-Cap Stocks
by Arpita Dutt
Diversify your portfolio by investing in blue-chip stocks with a proven track record and a certain level of financial strength, resilience & stability.
5 Top Performing Biotechnology Stocks of November
by Zacks Equity Research
November was a great month for pharma/biotech stocks after a rather difficult year when the industry struggled with media and political focus on high drug prices.
Buy 7 Stocks with Impressive Interest Coverage Ratio
by Zacks Equity Research
Interest Coverage Ratio is used to determine how effectively a company can pay the interest charges on its debt.
NVIDIA, Sotheby's Holdings, Celgene, Regeneron Pharmaceuticals and Sanofi highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
NVIDIA, Sotheby's Holdings, Celgene, Regeneron Pharmaceuticals and Sanofi highlighted as Zacks Bull and Bear of the Day
Celgene vs. Regeneron: Which Stock is a Better Pick?
by Arpita Dutt
Both Celgene (CELG) and Regeneron (REGN) are Zacks Rank #2 (Buy) stocks; which one of these two stocks is a better choice for investors?
The Zacks Analyst Blog Highlights: Allergan, Gilead Sciences, Pfizer, Regeneron Pharmaceuticals and Lion Biotechnologies
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Allergan, Gilead Sciences, Pfizer, Regeneron Pharmaceuticals and Lion Biotechnologies